CA-OPENGATE-CAPITAL
14.6.2019 09:02:10 CEST | Business Wire | Press release
OpenGate Capital , a global private equity firm, announced today that it has sold Omniplast BV (“Omniplast”) to a group of European investors composed of Reedcapital, Luigi M. Chiaraviglio, and Swiss Merchant Corporation. Omniplast was acquired by OpenGate in 2015 through the firm’s original, pre-fund investment in Ivy Group. Financial terms were not disclosed.
Andrew Nikou, OpenGate Capital’s founder and CEO commented, “We believe that Omniplast stands for global innovation in the fields of piping and fitting systems. I am incredibly proud of the efforts of OpenGate’s European team in the four years since acquiring Omniplast and have now fulfilled our mandate to exit the business at an ideal time. I wish the entire team at Omniplast an abundance of success under their new owners’ stewardship.”
The team at OpenGate Capital responsible for this investment and realization included: Julien Lagrèze, Partner; Sebastien Kiekert Le Moult, Partner; Marc Veillas, Managing Director; and Jonny Leppin, Senior Vice President.
Renaud Delaage, Partner at Reedcapital said, “Omniplast has a tremendous management team that will benefit greatly from the operational resources and entrepreneurial spirit that we will provide. We have a clear path to grow this business organically and through add-on acquisitions.”
Luigi M. Chiaraviglio added: “We are excited to contribute to the growth of this niche leader, whose products are exported globally, into its next phase of development.”
“We brought together investors sharing our philosophy of long-term value creation,” stated Filippo Sciorilli Borrelli, Managing Director of Swiss Merchant Corporation. Borrelli went on to say, “We are eager to start this journey.”
Luigi M. Chiaraviglio and Renaud Delaage led the transaction. Filippo Sciorilli Borrelli led the equity syndication for Swiss Merchant Corporation and played a key role in the execution.
Omniplast has earned a strong reputation and a loyal customer base within the agricultural and greenhouse sector. The business produces and distributes pressure and non-pressure PVC piping systems for the transportation of gases and fluids. Within its diverse product portfolio, Omniplast has developed five quality standards from three-layer non-pressure pipes, to irrigation and KIWA pressure pipes, to pipe-related specialties. The business is supported by forward integrated logistical solutions enabling efficient packaging and transportation. Headquartered in Veghel, The Netherlands, Omniplast has approximately 60 employees.
OpenGate Capital acquired Omniplast through its legacy, pre-fund portfolio as one of three businesses within Ivy Group. At acquisition, Omniplast had two entities in The Netherlands and Germany, which were separated in 2018 as part of a strategy to maximize each entity’s value. The German business, which specializes in PVC pipes for the residential market, was not included in the transaction.
The realization of Omniplast follows OpenGate Capital’s announcement that NAKAN, another division within Ivy Group, had been sold to Westlake Chemical Corporation in January of 2019.
About OpenGate Capital
Founded in 2005, OpenGate Capital is a global private equity firm that strives to acquire and optimize lower middle market businesses throughout North American and Europe. With a strategic international presence and a focus on corporate carve-outs and complex situations, the firm’s expertise allows it to realize a seller’s divestiture objectives while mitigating the risks associated with a business’s transition to independence. OpenGate is headquartered in Los Angeles and Paris and has a seasoned in-house team of professionals overseeing the entire lifecycle of each investment. To learn more about OpenGate, please visit www.opengatecapital.com .
About Reedcapital
Reedcapital is a private investment firm focused on the acquisition, transformation and development of lower-middle-market businesses. The firm invests in both performing and underperforming companies to create long term sustainable value. Typical investment opportunities are corporate divestitures and carve-out, complex situations and underperforming businesses. Reedcapital and its partners have been involved in over 30 transactions ranging from corporate divestitures, turnaround acquisitions, industry consolidations and other special situations investments across a wide array of industries and geographical markets. More information available on www.reedcapital.fr .
About Luigi M. Chiaraviglio
Luigi has been a private equity investor for more than 15 years, with Compass Partners in London first and Investindustrial in Milan, Lugano and New York later and has completed over 10 transactions for a value in excess of Eur 2bn including buyouts or expansion capital deals, restructurings, refinancing and exits and has been on the board of several companies in Europe and the USA. He is the Managing Director of Vista Investors, an investment firm operating through a multi-family office model, focusing on repositioning and expanding lower mid-market businesses or corporate group divisions. For more information please visit www.vista-investors.com .
About Swiss Merchant Corporation SA
Swiss Merchant Corporation(“SMC”), founded in 1990, is a corporate finance advisory boutique based in Lugano, Switzerland. SMC specializes in offering tailor made services for its clients aimed at long-term value creation. SMC’s one-stop-shop approach is designed to fulfill clients’ needs. SMC started as a private equity firm, successfully managing four investment funds from 1989 until 2015. Whilst maintaining an active role in direct investments and club deals, SMC has leveraged its experience as an advisor to its portfolio companies to focus on helping clients make informed financial decisions. More information available on www.swissmerchantcorporation.ch .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190614005028/en/
Contact:
OpenGate Media Contacts Alanna Chaffin Email: achaffin@opengatecapital.com Telephone: +1 (310) 432-7000
Mike Sitrick Sitrick & Company Email: Mike_Sitrick@sitrick.com Telephone: +1 (310) 788-2850
OpenGate Business Development Contact Joshua Adams Email: jadams@opengatecapital.com Telephone: +1 (310) 432-7000
Reedcapital Media Contact Email: media@reedcapital.fr Telephone: +33 1 72 74 10 31
Luigi M. Chiaraviglio Media Contact Email: media@vista-investors.com Telephone: +41 79 95 95 795
Swiss Merchant Corporation Media Contact Email: info@swimeco.ch Telephone: +41 91 2103568
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
